Annual Cost Of Goods Sold
$192.36 M
+$53.06 M+38.09%
31 December 2023
Summary:
Halozyme Therapeutics annual cost of goods sold is currently $192.36 million, with the most recent change of +$53.06 million (+38.09%) on 31 December 2023. During the last 3 years, it has risen by +$110.95 million (+136.28%). HALO annual cost of goods sold is now at all-time high.HALO Cost Of Goods Sold Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cost Of Goods Sold
$49.43 M
+$9.82 M+24.79%
30 September 2024
Summary:
Halozyme Therapeutics quarterly cost of goods sold is currently $49.43 million, with the most recent change of +$9.82 million (+24.79%) on 30 September 2024. Over the past year, it has dropped by -$2.87 million (-5.49%). HALO quarterly cost of goods sold is now -9.84% below its all-time high of $54.82 million, reached on 30 September 2023.HALO Quarterly Cost Of Goods Sold Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Cost Of Goods Sold
$169.66 M
-$5.40 M-3.08%
30 September 2024
Summary:
Halozyme Therapeutics TTM cost of goods sold is currently $169.66 million, with the most recent change of -$5.40 million (-3.08%) on 30 September 2024. Over the past year, it has dropped by -$22.70 million (-11.80%). HALO TTM cost of goods sold is now -11.80% below its all-time high of $192.36 million, reached on 31 December 2023.HALO TTM Cost Of Goods Sold Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HALO Cost Of Goods Sold Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | -5.5% | -11.8% |
| 3 y3 years | +136.3% | +129.0% | +108.4% |
| 5 y5 years | +322.3% | +196.2% | +272.5% |
HALO Cost Of Goods Sold High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +136.3% | -9.8% | +210.4% | -11.8% | +114.4% |
| 5 y | 5 years | at high | +343.6% | -9.8% | +787.7% | -11.8% | +402.2% |
| alltime | all time | at high | >+9999.0% | -9.8% | >+9999.0% | -11.8% |
Halozyme Therapeutics Cost Of Goods Sold History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $49.43 M(+24.8%) | $169.66 M(-3.1%) |
| June 2024 | - | $39.61 M(+39.8%) | $175.06 M(-5.6%) |
| Mar 2024 | - | $28.33 M(-45.8%) | $185.52 M(-3.6%) |
| Dec 2023 | $192.36 M(+38.1%) | $52.30 M(-4.6%) | $192.36 M(+5.6%) |
| Sept 2023 | - | $54.82 M(+9.5%) | $182.18 M(+4.3%) |
| June 2023 | - | $50.07 M(+42.4%) | $174.68 M(+10.2%) |
| Mar 2023 | - | $35.17 M(-16.5%) | $158.55 M(+13.8%) |
| Dec 2022 | $139.30 M(+71.1%) | $42.12 M(-11.0%) | $139.30 M(+17.3%) |
| Sept 2022 | - | $47.32 M(+39.4%) | $118.77 M(+31.9%) |
| June 2022 | - | $33.94 M(+113.2%) | $90.04 M(+13.8%) |
| Mar 2022 | - | $15.92 M(-26.2%) | $79.12 M(-2.8%) |
| Dec 2021 | $81.41 M(+87.7%) | $21.59 M(+16.1%) | $81.41 M(-5.4%) |
| Sept 2021 | - | $18.59 M(-19.2%) | $86.10 M(+17.8%) |
| June 2021 | - | $23.02 M(+26.3%) | $73.08 M(+31.0%) |
| Mar 2021 | - | $18.22 M(-30.7%) | $55.80 M(+28.7%) |
| Dec 2020 | $43.37 M(-4.8%) | $26.27 M(+371.8%) | $43.37 M(+28.4%) |
| Sept 2020 | - | $5.57 M(-3.0%) | $33.78 M(-33.2%) |
| June 2020 | - | $5.74 M(-0.8%) | $50.55 M(+8.3%) |
| Mar 2020 | - | $5.79 M(-65.3%) | $46.68 M(+2.5%) |
| Dec 2019 | $45.55 M(+349.3%) | $16.69 M(-25.3%) | $45.55 M(+32.1%) |
| Sept 2019 | - | $22.33 M(+1089.8%) | $34.48 M(+169.9%) |
| June 2019 | - | $1.88 M(-59.6%) | $12.77 M(+8.9%) |
| Mar 2019 | - | $4.65 M(-17.3%) | $11.73 M(+15.8%) |
| Dec 2018 | $10.14 M(-67.5%) | $5.62 M(+798.1%) | $10.14 M(-15.5%) |
| Sept 2018 | - | $626.00 K(-25.1%) | $12.00 M(-39.1%) |
| June 2018 | - | $836.00 K(-72.6%) | $19.71 M(-26.1%) |
| Mar 2018 | - | $3.05 M(-59.2%) | $26.66 M(-14.4%) |
| Dec 2017 | $31.15 M(-6.2%) | $7.49 M(-10.1%) | $31.15 M(-1.6%) |
| Sept 2017 | - | $8.33 M(+7.0%) | $31.67 M(-2.5%) |
| June 2017 | - | $7.79 M(+3.2%) | $32.47 M(-1.6%) |
| Mar 2017 | - | $7.54 M(-5.7%) | $32.99 M(-0.7%) |
| Dec 2016 | $33.21 M(+13.5%) | $8.00 M(-12.4%) | $33.21 M(-1.3%) |
| Sept 2016 | - | $9.13 M(+9.9%) | $33.63 M(+9.6%) |
| June 2016 | - | $8.31 M(+7.0%) | $30.68 M(+0.5%) |
| Mar 2016 | - | $7.76 M(-7.9%) | $30.51 M(+4.3%) |
| Dec 2015 | $29.25 M(+28.7%) | $8.43 M(+36.4%) | $29.25 M(+8.5%) |
| Sept 2015 | - | $6.18 M(-24.1%) | $26.96 M(+4.0%) |
| June 2015 | - | $8.14 M(+25.4%) | $25.93 M(+9.4%) |
| Mar 2015 | - | $6.49 M(+5.6%) | $23.71 M(+4.3%) |
| Dec 2014 | $22.73 M | $6.15 M(+19.6%) | $22.73 M(+13.0%) |
| Sept 2014 | - | $5.14 M(-13.2%) | $20.13 M(+28.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2014 | - | $5.92 M(+7.3%) | $15.67 M(+42.1%) |
| Mar 2014 | - | $5.52 M(+55.9%) | $11.03 M(+76.5%) |
| Dec 2013 | $6.25 M(+470.9%) | $3.54 M(+418.3%) | $6.25 M(+85.9%) |
| Sept 2013 | - | $683.00 K(-46.8%) | $3.36 M(+15.7%) |
| June 2013 | - | $1.28 M(+73.7%) | $2.90 M(+64.7%) |
| Mar 2013 | - | $739.00 K(+13.1%) | $1.76 M(+61.1%) |
| Dec 2012 | $1.09 M(+324.4%) | $653.50 K(+188.4%) | $1.09 M(+120.3%) |
| Sept 2012 | - | $226.60 K(+58.4%) | $496.70 K(+76.3%) |
| June 2012 | - | $143.10 K(+102.1%) | $281.80 K(-11.1%) |
| Mar 2012 | - | $70.80 K(+26.0%) | $316.90 K(+22.9%) |
| Dec 2011 | $257.80 K(-73.8%) | $56.20 K(+380.3%) | $257.80 K(-76.4%) |
| Sept 2011 | - | $11.70 K(-93.4%) | $1.09 M(+0.4%) |
| June 2011 | - | $178.20 K(+1423.1%) | $1.09 M(+9.6%) |
| Mar 2011 | - | $11.70 K(-98.7%) | $991.30 K(+0.6%) |
| Dec 2010 | $985.30 K(+215.9%) | $888.90 K(>+9900.0%) | $985.30 K(+284.3%) |
| Sept 2010 | - | $7200.00(-91.4%) | $256.40 K(-27.1%) |
| June 2010 | - | $83.50 K(+1364.9%) | $351.80 K(+12.3%) |
| Mar 2010 | - | $5700.00(-96.4%) | $313.40 K(+0.5%) |
| Dec 2009 | $311.90 K(-6.1%) | $160.00 K(+55.9%) | $311.90 K(+11.7%) |
| Sept 2009 | - | $102.60 K(+127.5%) | $279.20 K(-9.1%) |
| June 2009 | - | $45.10 K(+973.8%) | $307.30 K(+2.7%) |
| Mar 2009 | - | $4200.00(-96.7%) | $299.30 K(-9.9%) |
| Dec 2008 | $332.30 K(+38.2%) | $127.30 K(-2.6%) | $332.30 K(+41.9%) |
| Sept 2008 | - | $130.70 K(+252.3%) | $234.20 K(+43.7%) |
| June 2008 | - | $37.10 K(-0.3%) | $163.00 K(-19.1%) |
| Mar 2008 | - | $37.20 K(+27.4%) | $201.40 K(-16.2%) |
| Dec 2007 | $240.40 K(-45.0%) | $29.20 K(-50.9%) | $240.40 K(-4.8%) |
| Sept 2007 | - | $59.50 K(-21.2%) | $252.60 K(-54.0%) |
| June 2007 | - | $75.50 K(-0.9%) | $549.20 K(+12.0%) |
| Mar 2007 | - | $76.20 K(+84.1%) | $490.20 K(+12.2%) |
| Dec 2006 | $437.00 K(+740.4%) | $41.40 K(-88.4%) | $437.00 K(+4.9%) |
| Sept 2006 | - | $356.10 K(+2058.2%) | $416.50 K(+490.8%) |
| June 2006 | - | $16.50 K(-28.3%) | $70.50 K(-6.0%) |
| Mar 2006 | - | $23.00 K(+10.0%) | $75.00 K(+44.2%) |
| Dec 2005 | $52.00 K(+227.0%) | $20.90 K(+106.9%) | $52.00 K(+67.2%) |
| Sept 2005 | - | $10.10 K(-51.9%) | $31.10 K(+48.1%) |
| June 2005 | - | $21.00 K(-251.1%) | $21.00 K(>+9900.0%) |
| Dec 2002 | - | -$13.90 K(-486.1%) | $0.00(-100.0%) |
| Sept 2002 | - | $3600.00(-52.0%) | $13.90 K(+35.0%) |
| June 2002 | - | $7500.00(+167.9%) | $10.30 K(+267.9%) |
| Mar 2002 | - | $2800.00 | $2800.00 |
| Dec 2001 | $15.90 K | - | - |
FAQ
- What is Halozyme Therapeutics annual cost of goods sold?
- What is the all time high annual cost of goods sold for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly cost of goods sold?
- What is the all time high quarterly cost of goods sold for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly cost of goods sold year-on-year change?
- What is Halozyme Therapeutics TTM cost of goods sold?
- What is the all time high TTM cost of goods sold for Halozyme Therapeutics?
- What is Halozyme Therapeutics TTM cost of goods sold year-on-year change?
What is Halozyme Therapeutics annual cost of goods sold?
The current annual cost of goods sold of HALO is $192.36 M
What is the all time high annual cost of goods sold for Halozyme Therapeutics?
Halozyme Therapeutics all-time high annual cost of goods sold is $192.36 M
What is Halozyme Therapeutics quarterly cost of goods sold?
The current quarterly cost of goods sold of HALO is $49.43 M
What is the all time high quarterly cost of goods sold for Halozyme Therapeutics?
Halozyme Therapeutics all-time high quarterly cost of goods sold is $54.82 M
What is Halozyme Therapeutics quarterly cost of goods sold year-on-year change?
Over the past year, HALO quarterly cost of goods sold has changed by -$2.87 M (-5.49%)
What is Halozyme Therapeutics TTM cost of goods sold?
The current TTM cost of goods sold of HALO is $169.66 M
What is the all time high TTM cost of goods sold for Halozyme Therapeutics?
Halozyme Therapeutics all-time high TTM cost of goods sold is $192.36 M
What is Halozyme Therapeutics TTM cost of goods sold year-on-year change?
Over the past year, HALO TTM cost of goods sold has changed by -$22.70 M (-11.80%)